- Home
- Products
- Customized ADCs
- PDGFRA
- Anti-PDGFR (Tovetumab)-MC-MMAF ADC
Anti-PDGFR (Tovetumab)-MC-MMAF ADC (CAT#: ADC-W-1714)
This ADC product is comprised of an anti-PDGFR monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- PDGFRA
- Alternative Names
- PDGFRA; platelet-derived growth factor receptor, alpha polypeptide; platelet-derived growth factor receptor alpha; CD140a; PDGFR2; PDGFR-alpha; PDGF-R-alpha; CD140a antigen; PDGFRA/BCR fusion; CD140 antigen-like family member A; platelet-derived growth factor receptor 2; alpha-type platelet-derived growth factor receptor; rearranged-in-hypereosinophilia-platelet derived growth factor receptor alpha fusion protein; CD140A; PDGFR-2; RHEPDGFRA; MGC74795;
- Target Entrez Gene ID
- 5156
- Target UniProt ID
- P16234
- Overview
- This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.
- Overview
- Human Anti-PDGFRA IgG2-kappa antibody, Tovetumab
- Generic name
- Tovetumab
- Host animal
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IFNA1 (Faralimomab)-SMCC-DM1 ADC (CAT#: ADC-W-1220)
- Anti-MUC1 (Pemtumomab)-SPDB-DM4 ADC (CAT#: ADC-W-2427)
- Anti-ERBB2 (Trastuzumab)-Mc-MMAF ADC (CAT#: ADC-W-549)
- Anti-NGF (Fulranumab)-SMCC-DM1 ADC (CAT#: ADC-W-1658)
- Anti-B. anthracis PA (Raxibacumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2041)
- Anti-CD74-hindered disulfide-Doxorubicin ADC (CAT#: ADC-W-378)
- Anti-EGFR (Imgatuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1065)
- Anti-TNFRSF8 (cCA10)-β-glucuronide-doxorubicin propyloxazoline (DPO) ADC (CAT#: ADC-W-353)
- Anti-FUT4 (Fanolesomab)-MC-MMAF ADC (CAT#: ADC-W-2458)
- Anti-IL4 (Pascolizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1376)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1714. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1707 | Anti-PDGFR (Olaratumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1706 | Anti-PDGFR (Olaratumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1715 | Anti-PDGFR (Tovetumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1710 | Anti-PDGFR (Olaratumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1709 | Anti-PDGFR (Olaratumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-485 | Anti-EphA2 (clone 1C1)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-515 | Anti-EGFR (ABT-806)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-322 | Anti-CD19 (clone hBU12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-114 | Anti-CD33 (clone m2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
| ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2573 | Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2561 | Anti-MSLN (Anetumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
